Introduction
Polo-like kinase 1 (Plk1) is a key regulator of progression through mitosis. Although Plk1 seems to be dispensable for entry into mitosis, its role in spindle formation and exit from mitosis is crucial (Eckerdt and Strebhardt, 2006) . Plk1 is overexpressed in human tumors and has prognostic potential in cancer (Strebhardt and Ullrich, 2006) . Previously, our laboratory reported that Plk1 is highly expressed in hepatoblastoma samples and patients with a high expression of Plk1 showed significantly poorer prognosis than those with a low expression (Yamada et al., 2004) , indicating Plk1's involvement in carcinogenesis and its potential as a therapeutic target in liver cell malignancy. In fact, depletion of Plk1 by small interfering RNA (siRNA) treatment resulted in the arrest of cellcycle progression at the G2/M phase, such that proliferation was dramatically reduced and apoptosis increased in multiple cancer cell lines (Strebhardt and Ullrich, 2006) ; however, the downstream effectors and the molecular mechanism of Plk1-depletion-induced apoptosis have not been identified in detail. In the previous paper, we found that Plk1 inhibits the pro-apoptotic function of p53 through physical interaction and that Plk1 has the ability to bind to and phosphorylate transactivating (TA)p73 at Thr27, thereby inhibiting its transcriptional as well as pro-apoptotic activity (Koida et al., 2008) , suggesting that p53 family molecules have a significant function in Plk1-depletion-induced apoptosis in cancer cells.
The p63 gene has strong homology to the tumor suppressor p53 and the related gene, p73. p63 is actually the oldest evolutionary conserved member of the p53 family phylogenetically (Blandino and Dobbelstein, 2004) . It is a tumor suppressor gene and the most frequent site of genetic alterations in human cancers (Vousden and Lu, 2002) . p53 protein is a transcription factor that regulates the expression of a wide variety of genes involved in cell-cycle arrest and apoptosis in response to genotoxic or cellular stress (Levine, 1997; Yang et al., 1998) . Post-translational modification of p53 families is a key to their regulation. By contrast, reports on p63 phosphorylation are limited and its analysis remains to be confirmed (Westfall et al., 2005; Suh et al., 2006; MacPartlin et al., 2008) . In general, many functional parallels are found among p53, TAp73 and TAp63. When ectopically overexpressed in cell culture, TAp63 and TAp73 closely mimic the transcriptional activity and the biological function of p53. In reporter assays, p63/73-responsive promoters include well-known p53 target genes involved in anti-proliferative and pro-apoptotic cellular stress responses such as p21 Cip1/WAF1 , 14-3-3s, Bax, and so on (Candi et al., 2007) . Furthermore, both p63 and p73 isoforms contribute to the regulation of cell survival and apoptosis in human tumors (Moll and Slade, 2004) . Indeed, their ability to regulate apoptosis is clearly a major mechanism by which these genes contribute to human tumorigenesis (Rocco et al., 2006) . Initial studies in mice have shown the pro-apoptotic activity of endogenous p63 and p73. Germline deletion of p63 or p73 yielded mouse embryo fibroblasts (MEFs) that were less sensitive to DNAdamage-induced apoptosis than to wild-type cells when transformed by adenoviral E1A protein (Flores et al., 2002) . Although the above-mentioned lines of evidence indicate that p63 has an important function in DNA damage, controlling cell-cycle arrest and apoptosis, and in human cancer, its precise role in tumorigenesis remains to be elucidated. For example, unlike p53, p63 is rarely mutated in human cancers (Kato et al., 1999) , thus indicating it is not a canonical tumor suppressor. Furthermore, a potential role for p63 in carcinogenesis is supported by the finding of p63 genomic locus amplification and/or overexpression in more than 80% of primary head and neck squamous cell carcinoma as well as in other squamous epithelial cell malignancies (Massion et al., 2003) . On the other hand, some tumor types have been reported to lose p63 expression, suggesting the acceleration of tumorigenesis by p63 downregulation (Urist et al., 2002; Koga et al., 2003) .
In liver cell malignancy, the precise role of p63 in tumorigenesis and its clinical significance have not been elucidated. Liver cancer ranks fifth in the world among human cancers for incidence and third for mortality (Parkin et al., 2001) . Hepatocellular carcinoma (HCC), the most common malignant tumor of the liver, has an extremely unfavorable prognosis (over 95% mortality after 5 years), because of, in particular, the resistance of HCC cells to chemotherapy or radiotherapy (Bruix and Llovet, 2002) . A high incidence of p53 mutation is observed in developing countries (53%; Shen and Ong, 2004) , although p53 missense mutations are observed in B25% of HCC samples from industrialized countries, where the tumor essentially develops from alcoholgenerated cirrhosis (Montesano et al., 1997) . Previous reports indicated that the expression of TAp63 and deltaNp63 in HCC cell lines and the upregulation of TAp63 in response to certain forms of DNA damage accompanied with the increase in p53 target gene transcription (Petitjean et al., 2005) and treatment of HCC with chemotherapeutic drugs resulted in a dramatic increase in TAp63alpha levels (Gressner et al., 2005) .
In this study, we have found that Plk1 directly binds to TAp63alpha and phosphorylates TAp63 at the Ser-52, resulting in inhibition of its transcriptional activities caused by acceleration of protein degradation. To the best of our knowledge, this is the first report to determine the phosphorylated serine residue in the TA domain of p63. Plk1-depletion-induced apoptosis and activated p53 pathway downstream effectors are partially cancelled by p63 depletion in HCC cells. Furthermore, our finding suggests the possibility that Plk1/p63 appears to be an important candidate for cancer stemcell-targeted therapy in liver cell malignancy.
Results

Physical and functional interaction between Plk1 and p63
First, we examined whether Plk1 interacts with TAp63. COS-7 cells were transiently transfected with the expression plasmid for FLAG-tagged Plk1 and/or HA-tagged TAp63alpha. Whole-cell lysates prepared from transfected cells were immunoprecipitated with a monoclonal anti-HA antibody, and the immunoprecipitates were analysed by immunoblotting with a monoclonal anti-FLAG antibody. As shown in Figure 1a , FLAG-Plk1 was co-immunoprecipitated with HA-TAp63, and the analysis of the anti-FLAG immunoprecipitates also showed that HA-TAp63 is co-immunoprecipitated with FLAG-Plk1.
Furthermore, endogenous interaction between Plk1 and p63 was also detected using HaCaT cells (Figure 1b) . These results indicate that Plk1 interacts with p63 in mammalian cultured cells. As HaCaT cells show a high expression level of deltaNp63, this Plk1 controls cancer cell death through TAp63 S Komatsu et al interaction was supposed to be between Plk1 and deltaNp63.
TAp63 binds to the kinase domain of Plk1 through its DNA-binding region Next, to map the p63-interacting domain on Plk1, we constructed FLAG-tagged Plk1 deletion mutants, including Plk1-(1-401), Plk1-(1-329) and Plk1-(1-98) (Figure 2a) . We then tested the interaction between TAp63alpha and each of these Plk1 deletion mutants. COS-7 cells were transfected with the expression plasmid encoding TAp63alpha and each Plk1 deletion mutant, and co-immunoprecipitation experiments were carried out to determine the interaction. We found that Plk1-(1-401) and Plk1-(1-329) retained the ability to bind to TAp63alpha, whereas Plk1-(1-98) did not (Figure 2b ). These results indicate that Plk1 physically interacts with TAp63alpha through its 99-329 amino acid residues. To identify the essential region of TAp63alpha required for the interaction with Plk1, we carried out in vitro pull-down assays. The indicated glutathione-S-transferase (GST)-TAp63alpha deletion mutants ( Figure 2c ) were purified with glutathione-sepharose beads. Each of these GST fusion proteins was incubated with radiolabeled FLAG-Plk1, which was generated by the in vitro transcription/ translation system in the presence of [ 35 S]methionine. As clearly shown in Figure 2d , radiolabeled FLAG-Plk1 was efficiently pulled down by , implying that the region between amino acid residues 282 and 353 of TAp63alpha is important for the interaction with Plk1. As this binding site is common between TAp63 and deltaNp63, in Figure 1b , it is believed that Plk1 binds to TAp63 as well as to deltaNp63.
Plk1 directly phosphorylates Ser-52 of TAp63
Furthermore, to address whether Plk1 could phosphorylate TAp63, we carried out an in vitro kinase reaction. GST and GST-TAp63alpha fusion proteins were incubated with the active form of Plk1 in the presence of [g 32 P]ATP. The reaction mixtures were separated by SDS-polyacrylamide gel electrophoresis (PAGE) and subjected to autoradiography (Figure 3a) . The results suggested that Plk1 phosphorylates the region between amino acid residues 20 and 96 of TAp63.
As described earlier (Nakajima et al., 2003) , a sequence (D/E)X(S/T)FD/E) (where X is any amino acid and F a hydrophobic amino acid) was identified as a consensus motif for Plk1-dependent phosphorylation. According to the search for a putative phosphorylation site targeted by Plk1 within the amino acid sequence of TAp63 (residues 20-96), we identified related motifs, (39EPSEDG44 and 50EISMDC55), in the NH2-terminal portion of TAp63alpha (Figure 3b ).
To further confirm whether Ser-41 or Ser-52 of TAp63 could be phosphorylated by Plk1, we generated a mutant form of GST-p63-(1-102), termed as 'S41A' and 'S52A,' where Ser-41 or Ser-52 was substituted to Ala. Purified GST fusion proteins were subjected to the in vitro kinase reaction. As shown in Figure 3c , GST-TAp63-(1-102) and S41A mutant were strongly radiolabeled in the presence of Plk1, whereas S52A mutant was not labeled, indicating that Ser-52 of TAp63 is at least one of the phosphorylation sites targeted by Plk1, and is located in the transcriptional domain of TAp63. In addition, it seemed to be interesting that the molecular size of the mutant p63(1-102)S52A was smaller than that of p63 (1-102)S41A and p63(1-102), suggesting the effect of phosphorylation of S52 of TAp63 on the molecular weight of the 1-102 peptide.
Plk1 represses TAp63-mediated transcriptional activation
To address the effect of Plk1 on the transcriptional activity of TAp63, we carried out luciferase reporter assays. H1299 cells were co-transfected with a constant amount of the expression plasmid for TAp63alpha, the luciferase reporter construct carrying p53/p63-responsive p21
, BAX or MDM2 promoter and Renilla luciferase cDNA (pRL-TK) together with or without increasing amounts of FLAG-Plk1 expression plasmid. Enforced expression of FLAG-Plk1 significantly reduced luciferase activities driven by the indicated promoters in a dose-dependent manner ( Figure 4a ). These results suggest that Plk1 has the ability to repress the transcriptional activity of TAp63. Furthermore, to examine whether the kinase activity of Plk1 could be necessary for the inhibition of TAp63 function, we tested the possible effect of the kinase-deficient mutant form of Plk1, Plk1(K82M) (Supplementary data) on TAp63. For this purpose, we first examined whether Plk1(K82M) could interact with TAp63 in cells. The interaction between TAp63alpha and Plk1(K82M) was confirmed bi-directionally ( Figure 4b ). These results suggest that the kinase-deficient mutant form of Plk1 retains the ability to interact with TAp63 in cells. To further examine the effect of the kinase activity of Plk1 on TAp63 function, we carried out luciferase reporter assays. H1299 cells were co-transfected with a constant amount of the expression plasmid for TAp63alpha, a luciferase reporter construct bearing p53/p63-responsive p21
, BAX or MDM2 promoter and Renilla luciferase cDNA together with or without increasing amounts of FLAG-Plk1(K82M). As shown in Figure 4c , FLAG-Plk1(K82M) had a negligible effect on the transcriptional activity of TAp63. Collectively, these results indicate that kinase activity of Plk1 is required for the inhibition of TAp63 function.
Plk1 reduces the protein stability of TAp63 by its phosphorylation and suppresses TAp63-induced cell death Next, we checked the effect of Plk1 on TAp63-induced cell death. H1299 cells were transfected with mock, TAp63alpha, TAp63alpha/Plk1 or TAp63alpha/KD Plk1, and at 24 h after transfection, the cells were observed. TAp63alpha-transfected cells showed the inhibition of cell growth and increase in shrunken and floating cells compared with mock transfection; Plk1 (1-401) In vitro pull-down assay. An equal amount of radiolabeled FLAGPlk1 was incubated with GST or GST-TAp63alpha fusion proteins. After incubation, GST or GST-TAp63alpha fusion proteins was recovered by glutathione-Sepharose beads, and bound materials were resolved by 10% SDS-PAGE (polyacrylamide gel electrophoresis) followed by autoradiography.
Plk1 controls cancer cell death through TAp63 S Komatsu et al however, these phenomena were attenuated by cotransfection of Plk1, and KD Plk1 failed to attenuate it ( Figure 5a ). To study the molecular mechanism of the effect of Plk1-induced phosphorylation on the function of TAp63, we checked the protein stability of TAp63al-pha in the presence of Plk1 or KD Plk1(K82M). As shown in Figures 5b and c, Plk1 clearly decreased the protein stability of TAp63alpha. On the other hand, KD Plk1(K82M) did not modify the protein stability of TAp63alpha. In addition, the Plk1-related degradation of TAp63 was not attenuated by a proteasome inhibitor MG132 (data not shown), consistent with the phenomenon in TAp73/Plk1 experiments (Koida et al., 2008) . These results suggest that Plk1 downregulates the protein stability of TAp63 by its phosphorylation through a proteasome-independent pathway and suppresses TAp63-induced cell death.
Expression of Plk1 and p63 in liver tumor cells Earlier our laboratory reported that Plk1 is highly expressed in hepatoblastoma samples and that patients with a high expression of Plk1 showed significantly poorer prognosis than those with a low expression (Yamada et al., 2004) , indicating Plk1 involvement in carcinogenesis and its potential as a therapeutic target in liver cell malignancy. As the above results indicate the significance of Plk1/TAp63 in the regulation of cell death of cancer cells, we studied the expression level of Plk1 and p63 in liver tumor cell lines (Figure 6a ). We used one hepatoblastoma cell line (Huh6) and five HCC cell lines. From the results of reverse transcription (RT)-PCR and western blotting, a considerable expression of Plk1 was observed in liver tumor cell lines. Also, TAp63 was expressed in all liver tumor cell lines and the deltaNp63 expression was observed in HLF and PLC/ PRF/5 cells.
Significance of TAp63 in Plk1 knockdown-induced apoptosis of liver tumor cells Next, we carried out a knockdown experiment of Plk1 using siRNA in liver tumor cells (Huh6, HLE and HLF cells). FACS analysis suggested that Plk1 knockdown induced an increase in the sub-G0/G1 fraction not only in p53 wild-type Huh6 cells but also in p53 mutant-type HLE cells ( Figure 6b ). As p53 is mutated in HLE cells, this suggested the significance of TAp63 and/or p73 in Plk1 knockdown-induced apoptosis of liver tumor cells; however, the sub-G0/G1 fraction did not increase in HLF cells. In both HLE and HLF cells, p53 was mutated, and TAp63 and p73 were considerably expressed, although the expression of deltaNp63 was detected only in HLF cells (Figure 6a and Supplementary data), suggesting the possible anti-apoptotic effect of deltaNp63 in Plk1 knockdown-induced apoptosis. Next, we studied the influence of Plk1 knockdown on p53 family downstream effectors in liver tumor cells by RT-PCR experiments (Figure 6c ). Plk1 knockdown transactivated the p53 family downstream effectors p21
Cip1/WAF1
, GADD45 and PUMA in Huh6 cells, and p21
Cip1/WAF1 , 14-3-3s and PUMA in HLE cells. As a result of Plk1 single knockdown, we found significant TAp63 in Plk1 knockdown-induced apoptosis pathways. Next, we carried out double knockdown experiments of Plk1/TAp63 using HLE cells. Plk1 single knockdown increased cell death, but this was suppressed by double knockdown of Plk1/TAp63 (Figure 6d) . Furthermore, we examined the influence of double knockdown of Plk1/TAp63 on the expression of p53 family downstream effectors by RT-PCR (Figure 6e) . PUMA, 14-3-3s and p21
Cip1/WAF1 expression levels were increased by Plk1 single knockdown, and double knockdown of Plk1 and TAp63 successfully abolished the increase in p53 family downstream effectors by the single knockdown. Plk1 controls cancer cell death through TAp63 S Komatsu et al Possible role of Plk1/p63 in cancer stem cell fraction of liver tumor cells Previous research showed that the involvement of Plk1 is crucial for the metaphase-anaphase transition. Plk1 mRNA and protein levels are coordinately regulated during cell-cycle progression and are highest in the mitotic phase (Winkles and Alberts, 2005; Eckerdt and Strebhardt, 2006) . These observations suggested that Plk1 expression may be modest in the cancer stem cell fraction and that have a less significant role in cell death as cancer stem cells are generally accumulated in the Go/G1 phase (Zhou and Zhang, 2008) . To examine expression levels of Plk1 and p63 in the cancer stem cell fraction, we carried out real-time PCR using the side population (SP) fraction and non-SP fraction of liver tumor cells. Surprisingly, the result suggested that both Plk1/p63 are highly expressed in the SP fraction compared with in the non-SP fraction (Figure 7a ). Furthermore, the expression level of TAp63 was higher than that of deltaNp63 in the SP fraction of Huh7 cells, and almost equal to PLC/PRF/5 cells (Figure 7b ). An analysis of the p63 downstream molecules in the SP and non-SP fraction indicated that p63 activities were repressed in the SP fraction except for the p21 activation in PLC/PRF/5 cells (Figure 7c ), suggesting the possibility that p21 might be induced in a p53/TAp63-independent manner. These results suggest the considerable role of Plk1/p63 in the development of cancer stem cell-targeted therapy for liver tumor cells.
Discussion
Post-translational modification of p53 family members is a key phenomenon in their regulation (Shieh et al., 1997) ; however, the regulation of p63 through posttranslational modification has been studied only recently (Huang et al., 2004; Ghioni et al., 2005) . From these studies, it has been suggested that p63 protein levels can change rapidly as a result of post-translational mod- Cip1/WAF1 , BAX or MDM2 promoter and 10 ng of Renilla luciferase reporter plasmid (pRL-TK) in the presence or absence of increasing amounts of FLAG-Plk1 expression plasmid (a) or FLAG-Plk1(K82M) expression plasmid (c) (50, 100 and 200 ng). To standardize the amounts of plasmid DNA per transfection, pcDNA3 was added to yield 510 ng of plasmids. At 48 h after transfection, cells were lysed, and their luciferase activities were measured. Data were normalized and presented as mean values ± s.d. of three independent experiments. (b) Plk1(K82M) retains the ability to interact with TAp63 in cells. COS-7 cells were transiently transfected with FLAG-KD Plk1 and/or HA-TAp63 expression plasmids, immunoprecipitated with monoclonal anti-HA antibody (clone 3F10, Roche) and monoclonal anti-FLAG antibody (clone M2, Sigma), and immunoblotted with monoclonal anti-FLAG antibody and monoclonal anti-p63 antibody (clone 4a4) as indicated, to observe the interaction.
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S Komatsu et al ification. At present, limited studies of the phosphorylation status of p63 have been reported (Westfall et al., 2005; Suh et al., 2006) . DNA damage induces both the phosphorylation of p63 and its binding to p53 cognate DNA sites, and these events are linked to oocyte death (Suh et al., 2006) . TAp63 is constitutively expressed in female germ cells during meiotic arrest and is essential in the process of DNA-damage-induced oocyte death not involving p53. Furthermore, the phosphorylation of TAp63g, but not deltaNp63g, by IkB kinase b (IKKb) was reported, although the exact amino acid residue for phosphorylation was not determined (MacPartlin et al., 2008) . The IKKb-related phosphorylation of TAp63g was also induced by g-radiation. Upon ultraviolet radiation, deltaNp63a was phosphorylated at the ser-66/68 (in TAp63a, Ser-160/162) residues and led to ubiquitin-mediated degradation, suggesting that the protein stability of deltaNp63 is controlled by phosphorylation of different amino acid residues compared with that of TAp63 (Westfall et al., 2005) . In this study, we reported that Plk1 directly interacts with p63 and the Ser-52 residue of TAp63 is phosphorylated by Plk1 (Figure 3 ). This Plk1-induced TAp63 phosphorylation might not to be related to the DNA-damage-induced phosphorylation of TAp63, as Plk1 was shown to be downregulated in response to DNA damage (Smits et al., 2000; van Vugt et al., 2001) ; however, the Ser-52 phosphorylation of TAp63 after DNA damage should be examined for the following reasons: (1) IKKb-induced phosphorylation of TAp63 was shown in the TA domain of TAp63g and was related to TAp63g stabilization in response to gradiation (MacPartlin et al., 2008) and (2) radiationinduced phosphorylation/activation of p63 in oocytes occurs in TAp63 but not in deltaNp63 (Suh et al., 2006) . Interestingly, the previously reported p63 phosphorylation was related to protein stabilization, upregulation of activity and induction of apoptotic cell death (Westfall et al., 2005; Suh et al., 2006) . This study, however, clarified that phosphorylation by Plk1 results in protein degradation and suppression of the transcriptional activity of TAp63alpha (Figure 5b) , consistent with the inactivation of transcriptional activity in p53 and p73alpha (Koida et al., 2008) . It can be noted that, this Plk1-related TAp63 degradation was affected by cell density of Hep3B cells (data not shown), suggesting that further analysis of p63 phosphorylation and its effect on degradation will be required in future.
The study of Ser-52 phosphorylation not only in DNA damage response but also in oncogene-related stimulation will contribute to understanding the exact role of Plk1-related tumorigenesis in many malignancies. Anti-phosphor-Ser-52 TAp63 antibody will be an indispensable tool for those studies and phosphorylation of Ser-52 among TAp63 isoforms, TAp63a/TAp63b/ TAp63g, should be addressed in various malignancies. Another interesting finding in our study is that both Plk1/p63 were highly expressed in the SP fraction of liver tumor cells compared with the non-SP fraction, although p63 downstream molecules were not induced in SP fraction except for p21 (Figure 7 ), suggesting that Plk1 has an important function in preventing apoptotic cell death in tumorigenesis through the inactivation of p53 family members in tumor-initiating cells; therefore, the functional interaction of this Plk1-p53 family protein appears to be a candidate for tumor-initiating cell-targeted therapy.
Despite strong and continuing emphasis on the involvement of the p53 family in tumorigenesis because of the tumor suppressive role of the founding member p53, it now seems evident that the remaining family members, p63 and p73, are highly involved in regulating the development of different tissues (Candi et al., 2007) . In particular, lines of evidence indicate that the main role of p63 lies in the regulation of epithelial development and, in particular, in the formation of the epidermis (Mills et al., 1999; Yang et al., 1999) ; however, the exact molecular regulation mechanism of TAp63/ deltaNp63 transcriptional activities related to development and tumor suppression remains to be elucidated. Recently, several target genes of TAp63 in epithelial development have been identified, for example, IKKa/ GATA-3 (Candi et al., 2006) , Jagged-1&-2 (Sasaki et al., (Koster et al., 2004) and p21 (Westfall et al., 2003) . We also reported that TAp63-dependent induction of growth differentiation factor 15 (GDF15) has a critical function in the regulation of keratinocyte differentiation (Ichikawa et al., 2008) . Investigation of the role of the Ser-52 phosphorylation of TAp63 in selective transactivation of these specific target genes will be an interesting research project to understand development regulation.
Furthermore, it was recently reported that Plk1 homozygous null mice were embryonic lethal and early Plk1À/À embryos failed to survive after the eight-cell stage. Immunocytochemistry studies showed that Plk1 null embryos were arrested outside the mitotic phase . These observations suggest that the Plk1/ p63 relationship may play an important role not only in later epithelial tissue organization but also in early embryonic development. 
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Materials and methods
Cell culture
The African green monkey kidney cell line COS-7, human lung carcinoma cell line H1299, human hepatoblastoma cell line Huh6, HCC cell lines Huh7, Hep3B, HLE, HLF and PLC/ PRF/5, and keratinocyte-like HaCaT cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum (Invitrogen, Carlsbad, CA, USA), 50 mg/ml of penicillin and streptomycin each (Invitrogen). These cells were incubated at 37 1C in an atmosphere containing 5% CO 2 .
RNA extraction and RT-PCR Total RNA extraction, cDNA synthesis and semi-quantitative RT-PCR were carried out as described earlier (Koida et al., 2008) . The specific primers were indicated as supplements (Supplementary data). The expression of GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was measured as an internal control.
SP analysis
Side population analyses were conducted as described earlier (Chiba et al., 2006) . We have studied the hepatocellular markers such as AFP (alpha-fetoprotein) or cytokeratin19 (CK19) of SP and non-SP cells that are obtained by sorting, and a large number of cells positive for both markers were observed in SP cells (Chiba et al., 2006) .
Quantitative real-time RT-PCR of Plk1 and TAp63
Polymerase chain reaction of TAp63 was carried out using TaqMan technology (Applied Biosystems, Foster City, CA, USA). Gene expression assay primer and probe mixes were used for TAp63 and GAPDH (assay IDs: Hs00186613_m1 and 4310884E, respectively), and reactions were carried out according to the manufacturer's protocol. Polymerase chain reaction of Plk1 was carried out using SYBR Green technology (Takara Bio, Otsu, Shiga, Japan). PCR was carried out using an ABI Prism 7700 Sequence Detection System (Perkin-Elmer/Applied Biosystems, Carlsbad, CA, USA). Primers were indicated in Supplementary data.
Protein extraction and western blot analysis
Extraction of cellular proteins, protein concentration analysis, SDS-PAGE, protein transfer and western blot analysis were carried out as described in Supplementary data. Cells were transfected with 10 nM of control siRNA or Plk1 siRNA. At 48 h after transfection, both floating and attached cells were collected by low-speed centrifugation. The cells were then stained with propidium iodide (50 mg/ml) in the presence of 50 mg/ml of RNase A for 30 min at room temperature. The DNA content indicated by propidium iodide staining was analysed using a FACSCalibur flow cytometer. (c) RT-PCR analysis of siRNA-mediated knockdown of endogenous Plk1 in liver tumor cells. Cells were transfected with 10 nM of control siRNA or Plk1 siRNA. At 48 h after transfection, total RNA was prepared and analysed for expression levels of p21 Cip1/WAF1 , GADD45, PUMA and 14-3-3s. Amplification of GAPDH serves as an internal control. (d) FACS analysis of siRNA-treated cells. HLE cells were transfected with TAp63 siRNA and/or Plk1 siRNA. To standardize the amounts of siRNA per transfection, control siRNA was added to yield 15 nM of siRNA. At 48 h after transfection, both floating and attached cells were collected by low-speed centrifugation. Cells were then stained with propidium iodide (50 mg/ml) in the presence of 50 mg/ml of RNase A for 30 min at room temperature. The DNA content indicated by propidium iodide staining was analysed using a FACSCalibur flow cytometer. (e) RT-PCR analysis of siRNA-treated cells. HLE cells were transfected with TAp63 siRNA and/or Plk1 siRNA. To standardize the amounts of siRNA per transfection, control siRNA was added to yield 15 nM of siRNA. At 48 h after transfection, total RNA was prepared and analysed for expression levels of p21 Cip1/WAF1 , PUMA and 14-3-3s. Amplification of GAPDH serves as an internal control.
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Immunoprecipitation and western blot analysis For the immunoprecipitation of Plk1 and p63, COS-7 cells were transiently transfected with 2 mg of the expression plasmids for FLAG-Plk1 and or HA-TAp63alpha using Lipofectamine 2000 Transfection Reagent (Invitrogen). Protein extraction was carried out as described earlier. The extracts were incubated with the monoclonal anti-FLAG (clone M2, Sigma, St Louis, MO, USA) or monoclonal anti-HA antibody (clone 3F10, Boehringer Roche, Mannheim, Germany) at 4 1C for 8 h. Immunocomplexes were precipitated with protein G-Sepharose beads at 4 1C for 30 min, which were then pelleted by centrifugation at 15 000 g for 5 min. The precipitates were washed with lysis buffer three times at 4 1C, resuspended in 30 ml of SDS sample buffer and treated at 100 1C for 5 min. Proteins were then resolved by 8% SDS-PAGE, and transferred onto Immobilon-P membranes (Millipore, Bedford, MA, USA). The protein complex was detected by western blot analysis using monoclonal anti-FLAG or monoclonal anti-p63 antibodies.
GST pull-down assay cDNA fragments encoding the indicated deletion mutants of TAp63alpha were generated by a PCR-based strategy, and subcloned into GST fusion protein expression plasmid pGEX-4T-1 (GE Healthcare, Piscataway, NJ, USA). GST and GSTTAp63alpha fusion proteins were expressed and purified using glutathione-Sepharose beads (Amersham Biosciences). FLAGPlk1 was radiolabeled in vitro using the TNT Quick Coupled transcription/translation system (Promega, Madison, WI, USA) in the presence of [ 35 S]methionine and incubated with GST or GST-TAp63alpha deletion mutants at 4 1C for 2 h. After the addition of 30 ml glutathione-Sepharose beads to the reaction mixture, incubation was continued at 4 1C for 1 h. The beads were collected by centrifugation and washed three times with binding buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Nonidet P-40 and 1 mM EDTA. The 35 S-labeledbound proteins were eluted using 2 Â SDS sample buffer and separated by 10% SDS-PAGE. After electrophoresis, the gel was dried and exposed to X-ray film with an intensifying screen.
Flow cytometry
After transfection, both floating and attached cells were collected by low-speed centrifugation and washed in phosphate-buffered saline. The cells were then stained with propidium iodide (50 mg/ ml) in the presence of 50 mg/ml of RNase A for 30 min at room temperature. The DNA content indicated by propidium iodide staining was analysed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA).
Luciferase reporter assay Luciferase reporter assay was carried out as described earlier (Koida et al., 2008) . Each experiment was carried out at least three times in triplicate.
In vitro kinase assay To identify the possible Ser residue(s) of TAp63alpha that could be phosphorylated by Plk1, we carried out in vitro kinase assay according to the previous report (Koida et al., 2008) . In brief, GST-TAp63alpha-(1-102), GST-S41A and GST-S52A were incubated with the active form of Plk1 (cat no. CY-E1163, CycLex, Nagano, Japan) in the presence of 10 mCi of [g-32 P]ATP (B6000 Ci/mmol, GE Healthcare) in 40 ml of kinase buffer (40 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 10 mM MgCl 2 , 1 mM dithiotreitol and 3 mM MnCl 2 ). Reactions were incubated at 30 1C for 30 min and terminated by the addition of Laemmli SDS sample dilution buffer. The reaction mixtures were separated by SDS-PAGE and subjected to autoradiography.
RNA interference
To knockdown endogenous Plk1, TAp63 and p73, cells were transiently transfected with the chemically synthesized siRNA targeting Plk1, TAp63 and p73 or with the control siRNA using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer's recommendations. Total RNA and whole-cell lysates were prepared 48 h after transfection. The specific sequences were as follows: Plk1, 5 0 -AACCAGUGGUUCGA GAGACAG-3 0 ; TAp63, 5 0 -GAUGGUGCGACAAACAA GA-3 0 ; and p73, 5 0 -CGGAUUCCAGCAUGGACGU-3 0 . Selected siRNA sequences were submitted to a BLAST search against the human genome sequence to ensure specificity. Silencer Negative Control #1 siRNA (Ambion, Austin, TX, USA) was used as control siRNA.
Construction of the deletion mutants of Plk1
For construction of the deletion mutants of Plk1, pcDNA3-FLAG-Plk1 was digested with BamHI, BamHI/BstXI and BamHI/NcoI for the fragments encoding amino acid residues 1-401, 1-329 and 1-98, respectively. These fragments were purified from agarose gels, filled in the overhangs with Klenow enzyme and then inserted in-frame into enzymatically modified BamHI and XhoI sites of the pcDNA3-FLAG expression plasmid to obtain pcDNA3-FLAG-Plk1-(1-401), pcDNA3-FLAG-Plk1-(1-329), and pcDNA3-FLAGPlk1-(1-98), respectively. DNA sequencing confirmed the authenticity of the expression plasmids before transfection.
